Navigation Links
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
Date:1/29/2013

BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the second quarter of fiscal 2013 on Monday, February 4, 2013, and will hold a conference call on Tuesday, February 5, 2013 at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer and Michael Carruthers , Chief Financial Officer will lead the call.

Conference Call InformationDate:Tuesday, February 5, 2013Time:9:00 a.m. eastern timeToll-Free:(800) 447-0521Toll:(847) 413-3238Pass Code:34113160Webcast & Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeA replay of the call will be available as a webcast on www.arraybiopharma.com About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.  Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma in the next several months as well as BRAF mutant melanoma later in 2013 (with Novartis).  Four other Array invented drugs are also approaching Phase 3 decisions by the end of calendar year 2013.  These include Array's wholly owned drugs, ARRY-614 and ARRY-520, and two additional partnered programs, selumetinib (with AstraZeneca) and danoprevir (with InterMune / Roche).  For more information on Array, please go to www.arraybiopharma.com.


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bar Harbor BioTechnology to Offer Direct Sales Starting in 2013; Development of StellARrays™ for C.elegans and Zebrafish Underway
2. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
3. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
4. John A. Orwin Joins Array BioPharma Board Of Directors
5. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
6. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
7. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
8. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
9. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
10. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
11. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):